The near term future, page-8

I don't think you got carried away at all, just following guidance you were getting. Even then one could make the case that fully following that guidance 58 would still be conservative.
I did the exercise with the $49-51m 2023 guidance in mind, trying to get there with as conservative an approach as possible. Also trying to come up with at least an idea of expenditures. Big jump in sales and marketing this year, smaller yet substantial next year with the new salesforce already in place. Cost of sales will be a little less than what I used since not every cost will go up equivalent to sales, but it's a conservative look. R&D should be down dramatically this year and next unless they announce something new.
One could run some extrapolations from some of JC's statements that would generate some eye popping numbers. But until we see how much entropy they encounter at trauma centers best to keep it simple.
Even using a very conservative approach they should be cash flow positive H1 of 2025. Don't think H2 of 2024 is out of the question.